Rea­ta culls bar­dox­olone, end­ing decade of R&D on trou­bled kid­ney dis­ease drug

Rea­ta’s long and wind­ing road with bar­dox­olone ap­pears to be over.

The Plano, TX-based biotech and part­ner Ky­owa Kirin said Wednes­day morn­ing that they are scrap­ping de­vel­op­ment of the as­set in chron­ic kid­ney dis­ease pro­grams, which in­clude CKD caused by Al­port syn­drome, peo­ple with di­a­bet­ic CKD and a rare, hered­i­tary form of the dis­ease.

With that, Rea­ta ex­pects to save more than $100 mil­lion pre­vi­ous­ly set aside for the drug, a move that will push run­way to the end of 2026, the com­pa­ny said in a pre­sen­ta­tion. Rea­ta al­so dis­closed a non-di­lu­tive $275 mil­lion debt fa­cil­i­ty as part of its first-quar­ter up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER